Back to results
US 9,078,913 B2Granted
Use of human Biliverdin reductase and fragments thereof protein kinase C-δ and ERK related conditions
AssigneeUniversity of Rochester
InventorMahin D. Maines
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods of modulating PKC-δ activity and PKC-δ/ERK complex activity in cells via biliverdin reductase. Methods and compositions for diagnosing and treating a PKC-δ and PKC-δ/ERK complex related condition are also disclosed.
Claims10
A method of modulating PKC-δ activity in a population of cells, said method comprising:
- administering to the population of cells a mammalian biliverdin reductase (BVR) peptide fragment that inhibits PKC-δ activity, the peptide fragment consisting of the amino acid sequence of FXFPXF[S/T]G (SEQ ID NO:
- 33), wherein X at amino acid positions 2 and 5 is any amino acid, under conditions effective to modulate PKC-δ activity in the population of cells.
A method of treating a PKC-δ related condition in a subject comprising:
- administering to the subject having the PKC-δ related condition a mammalian biliverdin reductase (BVR) peptide fragment that inhibits PKC-δ activity, the peptide fragment consisting of the amino acid sequence of FXFPXF[S/T]G (SEQ ID NO:
- 33), wherein X at amino acid positions 2 and 5 is any amino acid, under conditions effective to treat the PKC-δ related condition.
Dependencies are inferred from the claim text.